Solid Biosciences Inc.

SLDB Healthcare Biotechnology

Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.

5.53 0.21 −3.66%
Market cap
$615.5M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
n/a
Altman Z
−2.87
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
244.85 205.46 396.79 395.11
Total non-current assets
29.06 27.08 26.11 25.47
Total Assets
273.91 232.54 422.89 420.58
Total current liabilities
36.34 33.47 30.28 28.58
Total non-current liabilities
19.62 19.06 18.48 17.92
Total liabilities
55.97 52.53 48.76 46.51
Common Equity (Total)
217.95 180.01 374.13 374.08
Shareholders Equity (Total)
217.95 180.01 374.13 374.08

Show all line items

In millions of $ except per-share values · columns are period end dates